Results for
"[search-keyword]"
Sponsor content
162 result(s) found, displaying 11 to 20
-
Jul-2024Prescription medicine evaluationActive ingredient: tarlatamab.
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)Wezlana (ustekinumab) has been approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.